A number of other analysts have also recently weighed in on SMMT. Oppenheimer Holdings, Inc. reiterated a buy rating and set a $24.00 price target on shares of Summit Therapeutics PLC in a research note on Monday, October 16th. Zacks Investment Research cut shares of Summit Therapeutics PLC from a hold rating to a sell rating in a research note on Wednesday, October 11th. Finally, ValuEngine cut shares of Summit Therapeutics PLC from a hold rating to a sell rating in a research note on Thursday, October 5th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Summit Therapeutics PLC currently has an average rating of Hold and a consensus target price of $23.50.
Summit Therapeutics PLC (SMMT) traded up 3.16% on Monday, hitting $10.12. The stock had a trading volume of 14,901 shares. The firm’s market cap is $142.94 million. The company’s 50 day moving average price is $12.38 and its 200 day moving average price is $12.38. Summit Therapeutics PLC has a 52-week low of $7.95 and a 52-week high of $16.86.
Summit Therapeutics PLC (NASDAQ:SMMT) last issued its quarterly earnings results on Thursday, August 31st. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.28). The business had revenue of $25.01 million for the quarter, compared to analyst estimates of $31.37 million. Summit Therapeutics PLC had a negative return on equity of 29,334.40% and a negative net margin of 12.44%. Analysts expect that Summit Therapeutics PLC will post ($0.53) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/summit-therapeutics-plc-smmt-stock-rating-reaffirmed-by-canaccord-genuity/1720437.html.
A hedge fund recently bought a new stake in Summit Therapeutics PLC stock. Renaissance Technologies LLC purchased a new stake in Summit Therapeutics PLC (NASDAQ:SMMT) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 20,102 shares of the company’s stock, valued at approximately $267,000. Renaissance Technologies LLC owned approximately 0.16% of Summit Therapeutics PLC as of its most recent SEC filing. Hedge funds and other institutional investors own 19.71% of the company’s stock.
About Summit Therapeutics PLC
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with our FREE daily email newsletter.